Notice to Stakeholders – Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin

Health Canada is issuing this notice to clinical trial sponsors to clarify the approach to clinical research with psilocybin. Health Canada recognizes that conducting clinical research (i.e., research carried out on humans) is a critical step in the generation of good quality evidence needed to better understand the potential health benefits and harms associated with the therapeutic use of psilocybin.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Avis aux intervenants – Clarification des exigences en vertu du Règlement sur les aliments et drogues et de la Loi réglementant certaines drogues et autres substances lors de la réalisation d'une recherche clinique avec la psilocybine
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2022-01-07 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["avis aux intervenants", "clarification des exigences", "Règlement sur les aliments et drogues", "Loi réglementant certaines drogues et autres substances", "recherche clinique avec la psilocybine"], "en": ["notice to stakeholders", "clarification of requirements", "Food-and-Drug Regulations", "Controlled Drugs-and-Substances Act", "clinical-research with psilocybin"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source